South Korea · Delayed Price · Currency is KRW Pharmsville Statistics
Total Valuation
Pharmsville has a market cap or net worth of KRW 29.06 billion. The enterprise value is -9.91 billion.
| Market Cap | 29.06B |
| Enterprise Value | -9.91B |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Pharmsville has 7.73 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 7.73M |
| Shares Outstanding | 7.73M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 62.90% |
| Owned by Institutions (%) | n/a |
| Float | 2.00M |
Valuation Ratios
The trailing PE ratio is 10.05.
| PE Ratio | 10.05 |
| Forward PE | n/a |
| PS Ratio | 2.28 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | 15.37 |
| P/OCF Ratio | 15.34 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.43 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.24 |
Financial Position
The company has a current ratio of 21.76, with a Debt / Equity ratio of 0.00.
| Current Ratio | 21.76 |
| Quick Ratio | 20.95 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.01 |
| Interest Coverage | -755.77 |
Financial Efficiency
Return on equity (ROE) is 4.43% and return on invested capital (ROIC) is -2.03%.
| Return on Equity (ROE) | 4.43% |
| Return on Assets (ROA) | -0.62% |
| Return on Invested Capital (ROIC) | -2.03% |
| Return on Capital Employed (ROCE) | -1.01% |
| Weighted Average Cost of Capital (WACC) | 4.18% |
| Revenue Per Employee | 454.58M |
| Profits Per Employee | 103.16M |
| Employee Count | 28 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 2.73 |
Taxes
In the past 12 months, Pharmsville has paid 688.26 million in taxes.
| Income Tax | 688.26M |
| Effective Tax Rate | 19.17% |
Stock Price Statistics
The stock price has increased by +7.12% in the last 52 weeks. The beta is -0.01, so Pharmsville's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | +7.12% |
| 50-Day Moving Average | 3,526.70 |
| 200-Day Moving Average | 3,750.33 |
| Relative Strength Index (RSI) | 64.59 |
| Average Volume (20 Days) | 11,110 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmsville had revenue of KRW 12.73 billion and earned 2.89 billion in profits. Earnings per share was 374.00.
| Revenue | 12.73B |
| Gross Profit | 8.05B |
| Operating Income | -675.66M |
| Pretax Income | 3.59B |
| Net Income | 2.89B |
| EBITDA | -34.92M |
| EBIT | -675.66M |
| Earnings Per Share (EPS) | 374.00 |
Balance Sheet
The company has 39.11 billion in cash and 16.48 million in debt, with a net cash position of 39.09 billion or 5,058.01 per share.
| Cash & Cash Equivalents | 39.11B |
| Total Debt | 16.48M |
| Net Cash | 39.09B |
| Net Cash Per Share | 5,058.01 |
| Equity (Book Value) | 66.55B |
| Book Value Per Share | 8,616.98 |
| Working Capital | 39.58B |
Cash Flow
In the last 12 months, operating cash flow was 1.89 billion and capital expenditures -2.86 million, giving a free cash flow of 1.89 billion.
| Operating Cash Flow | 1.89B |
| Capital Expenditures | -2.86M |
| Depreciation & Amortization | 640.74M |
| Net Borrowing | -7.12M |
| Free Cash Flow | 1.89B |
| FCF Per Share | 244.68 |
Margins
Gross margin is 63.21%, with operating and profit margins of -5.31% and 22.69%.
| Gross Margin | 63.21% |
| Operating Margin | -5.31% |
| Pretax Margin | 28.21% |
| Profit Margin | 22.69% |
| EBITDA Margin | -0.27% |
| EBIT Margin | -5.31% |
| FCF Margin | 14.86% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 2.66%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 2.66% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 26.75% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 2.64% |
| Earnings Yield | 9.94% |
| FCF Yield | 6.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharmsville has an Altman Z-Score of 10.67 and a Piotroski F-Score of 4.
| Altman Z-Score | 10.67 |
| Piotroski F-Score | 4 |